Organization: Centre for Drug Research and Development

Innovation Conversations: Q&A with CDRD president and CEO Gordon C. McCauley

Vancouver-based Centre for Drug Research and Development (CDRD) is an 11-year-old organization that helps “bridge” scientific discoveries and commercialization in the life sciences sector. RE$EARCH MONEY spoke to CDRD president and CEO Gordon C. McCauley about how it is helping companies scale up and its strategy for attracting capital in a sector that is growing exponentially but is perceived to be risky.

Zucara Therapeutics secures funding for diabetes drug

Life sciences firm Zucara Therapeutics Inc. has secured non-dilutive funding of US$3.9 million for the pre-clinical advancement of its lead drug candidate for diabetes, ZT-01. Zucara’s partner, The Leona M. and Harry B. Helmsley Charitable Trust, will provide the funds in the form of a loan under a program-related investment (PRI). ZT-01 is focused on…

Feds announce chairs of Economic Strategy Tables

The federal government has appointed the chairs of four of the six Economic Strategy Tables that were announced in the last federal Budget as part of its new Innovation and Skills Plan. The industry leaders represent six high-growth sectors singled out by the government as having the best prospects for achieving innovative economic growth and…

Sepset study to fast track diagnosis of sepsis

Sepset Biosciences Inc has started a multi-country and multi-center clinical study to develop faster and more accurate identification of patients afflicted with sepsis. The study is expected to assist in validating and refining the proprietary gene signature of Sepset, which is a spin-out of the Centre for Drug Research and Development (CDRD). A successful development…

Canada’s regenerative medicine sector poised to soar with better funding and collaboration: report

Canadian expertise and achievements in regenerative medicine (RM) could be at a turning point if strategic steps are taken to increase stable funding and achieve greater coordination among the many federal and provincial players. Those are the key observations of a report issued by the Council of Canadian Academies (CCA), which was based on a two-day workshop held last October to provide policy makers with pointers for growing the sector and realizing greater economic and health benefits.

CDRD spin-off secures seed funding from Quark

Sitka Biopharma, Vancouver, has received a “significant” but unspecified seed investment from Quark Venture to advance its lead compound for treating bladder cancer into clinical trials. Sitka was spun out in 2013 from the Univ of British Columbia and the Centre for Drug Research and Development. CDRD assisted the firm in developing its nanoparticle platform…

Kairos and Zymeworks complete merger

Kairos Therapeutics Inc — a spin off of the Centre for Drug Research and Development — has completed its merger with Zymeworks Inc (R$, January 26/16). The merger will allow the Vancouver-based biotherapeutics companies to accelerate their respective platforms, resources and pipelines….

Biotech partnership may lead to merger

Two privately held Vancouver biotech firms have entered a strategic partnership that could lead to an eventual merger. Zymeworks Inc has made an equity investment in Kairos Therapeutics Inc — a spin off of the Centre for Drug Research and Development. Zymeworks specializes in bi-specific and multi-specific anybodies while Cairos discovers and develops antibody drug…

Vida and CDRD collaborate on drug development

Privately held Vida Therapeutics Inc is collaborating with the Centre for Drug Research and Development (CDRD) to advance its lead drug candidate to the commercial stage and position the firm for further private sector investment. CDRD synthesized and supplied the GzmB inhibitor drug compound to be used as a target for Vida’s therapeutic strategy. The…